Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
BERG to Present New Data Describing Details on Progress of its Oncology Portfolio and Precision Medicine Applications at the European Society for Medical Oncology 2018 Congress | ||
By: PR Newswire Association LLC. - 20 Oct 2018 | Back to overview list |
|
BOSTON, Oct. 19, 2018 /PRNewswire/ -- BERG LLC, a Boston-based biopharmaceutical company that merges biology with technology to map the nature of diseases, today announced the presentation of three posters on the progression of its oncology and artificial intelligence (AI)/Biomarker portfolio at the European Society of Medical Oncology (ESMO) 2018 Annual Congress being held October 19-23, 2018 in Munich, Germany. Key presentation highlights include:
"The data accepted for presentation further reinforce the power and value of our proprietary Interrogative Biology platform and promising early stage pipeline for the treatment of advanced pancreatic cancer and chemotherapy-induced alopecia, among other oncologic conditions," said Niven R. Narain, Ph.D., BERG Co-founder, President and Chief Executive Officer. "By taking a Back to Biology approach in combination with artificial intelligence, we are armed with greater understanding of disease biomarkers to guide our discovery and development efforts to effectively achieve therapeutic response and patient benefit through novel treatment options." Details of the poster presentations are as follows and are available via the ESMO 2018 Annual Congress website: Title: Streamlining Multi-Omic and Artificial Intelligence Analysis Through Interrogative Biology® and bAIcis® for Translational Precision Medicine Applications in Clinical Oncology Title: A Phase 2 Clinical Investigation of BPM 31510-IV (Ubidecarenone) in Patients with Advanced Pancreatic Cancer Title: A Phase I Safety Study of Topical Calcitriol (BPM 31543) for the Prevention of Chemotherapy-Induced Alopecia (CIA): Final Study Results About BPM 31510 About BPM 31543 About BERG Media Contact: BERG Investor Contact: View original content to download multimedia:http://www.prnewswire.com/news-releases/berg-to-present-new-data-describing-details-on-progress-of-its-oncology-portfolio-and-precision-medicine-applications-at-the-european-society-for-medical-oncology-2018-congress-300734635.html SOURCE BERG |
||
|
||
Copyright 2018 PR Newswire Association LLC. | Back to overview list |